Denise Faltischek

Tilray Medical, a division of Tilray Brands (NASDAQ:TLRY), announced the launch of its first commercial medical cannabis products cultivated in Germany. The debut comes from its Aphria RX facility, marking a milestone under the country's recently updated cultivation regulations, MedCanG. New...

On Thursday, Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc. (NASDAQ:TLRY), announced the final results of a new scientific study, “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).” Results showed that cannabis...

Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Wednesday the launch of Redecan EU-GMP certified medical cannabis products in Australia. What Happened: The following Redecan products are now available for medical cannabis patients in Australia...

Tilray Medical, a division of Canadian cannabis giant Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS). The study,...

Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday that Aphria RX GmbH has received a trading license in Germany. What Happened The new permit will allow the Canadian cannabis giant to sell and distribute a broad range of medical marijuana products to pharmacies, hospitals, and...

The second most populated country in Europe, Germany, legalized recently marijuana. What does this mean? Even though Germany's cannabis legalization is partial, it significantly impacts the country’s medical marijuana program, and by enabling personal possession, consumption and...

Tilray Brands (NASDAQ:TLRY) announced that its medical cannabis division, Tilray Medical "enthusiastically welcomes" the opening of the German medical cannabis market and the positive paradigm shift in German drug policy. Friday's landmark passage of the German Medical Cannabis Act represents a...

On Monday, Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY), announced its contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, which is a severe form of brain cancer. The clinical...

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) announced that its medical cannabis division, Tilray Medical and FL Group, the company’s subsidiary in Italy, have received authorization from Italy’s Ministry of Health to distribute three new medical cannabis compounds. These medical...

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) announced that its medical cannabis division, Tilray Medical, has expanded its European footprint across the Czech Republic through a new export and distribution partnership with Cansativa Group. The new strategic partnership broadens Tilray Medical...

Canadian cannabis giant, Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY), has successfully relaunched its EU GMP-produced medical cannabis oral solution in Ireland under the country’s Medical Cannabis Access Program (MCAP). Tilray’s approved product has also recently received...

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY), announced that FL Group S.R.L., a division of Tilray Medical in Italy, has received approval from the Italian Ministry of Health to import and distribute Tilray’s medical cannabis oral solution THC25 across the country. Denise Faltischek, Tilray...

Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY), has initiated a policy roundtable with German regulators on adult-use cannabis legalization in Germany. In this meeting, the German Drug Commissioner, Burkhard Blienert, presented the plan for adult-use cannabis legalization and repeated the German...

Tilray Brands, Inc.'s (NASDAQ: TLRY) (TSX:TLRY) Tilray Medical, has received approval to commercialize its Tilray branded medical cannabis products in Poland expanding its product offering and distribution across pharmacies in Europe. Denise Faltischek, Tilray’s chief strategy officer and...

Tilray Brands, Inc.’s (NASDAQ: TLRY) (TSX:TLRY) medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom. Denise Faltischek, Tilray’s chief strategy officer, and head of international business, stated, “The demand for medical...